Últimas noticias sobre Kaixin Hldgs (NASDAQ:KXIN) Bolsa

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

Kaixin Holdings

Kaixin Auto Holdings Warrants (30/04/2024)

Nokia Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) has reached a patent licensing agreement with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), granting the e-commerce giant access to Nokia&#8217;s video technologies for its streaming services and devices.
The agreement revealed on Monday settles all outstanding <a href="https://www.nokia.com/about-us/news/releases/2025/03/31/nokia-and-amazon-sign-patent-agreement/" target="_blank" rel="noreferrer noopener">patent </a>disputes between the two firms in multiple regions.
The financial and contractual details of the agreement have been kept confidential, as mutually agreed upon by both parties; this agreement represents a key resolution between the technology companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44532830/rocket-lab-joins-us-space-forces-5-6-billion-launch-program-stock-soars" rel="noreferrer noopener">Rocket Lab Joins US Space Force&#8217;s $5.6 Billion Launch Program</a>
Over the past 25 years, the Finnish telecom giant has developed nearly 5,000 innovations that improve multimedia products and services.
The company has made significant investments in research and development, surpassing 150 billion euros (~$162 billion) since 2000. In 2024 alone, it allocated over 4.5 billion euros to further innovations in cellular networks and multimedia technologies.
The agreement grants Amazon the ability to incorporate Nokia&#8217;s patented video technologies into its streaming services and devices, aiming to enhance efficiency and optimize content delivery.
&#8220;&#8221;We are pleased to have reached agreement on the use of Nokia&#8217;s video technologies in Amazon&#8217;s streaming services and devices,&#8221; said Arvin Patel, Chief Licensing Officer New Segments at Nokia.
Price Action: NOK shares traded lower by 0.77% at $5.17 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44533913/lockheed-martin-and-google-partner-to-advance-ai-in-defense" target="_blank" rel="noreferrer noopener">Lockheed Martin And Google Partner To Advance AI In Defense</a></li>
</ul>
Image via Shutterstock.

Equities

News

Movers

General

AMZN

Nokia, Amazon End Patent Dispute With Major Licensing Pact for Streaming Innovation

Pursuant to the terms of the merger agreement, Southern States' shareholders will receive 0.800 shares of FB Financial common stock for each share of Southern States stock. Based on FB Financial's closing stock price of $47.05 per share as of March 28, 2025, the implied transaction value is approximately $37.64 per Southern States share, or $381 million, in the aggregate

SBKFF

FB Financial To Acquire Southern States In $381M All-Stock Deal, Expanding Reach Across Alabama And Georgia

FiscalNote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>), the leading provider of AI-driven policy and regulatory intelligence solutions, today announced the launch of its EU Defense and Space Policy vertical. This launch equips users with enhanced visibility into previously unavailable data and insights in critical areas such as space, defense industry, internal security, crisis management, and related strategic initiatives, overlaid with expanded tracking capabilities. Through their use of this powerful new offering, FiscalNote customers will gain a critical edge in anticipating and responding to impactful EU-level policy shifts.
With the ongoing war in Ukraine and shifting global alliances, the European Union (EU) is strengthening its response to a rapidly changing geopolitical landscape, aiming to boost its manufacturing capacity and reduce reliance on non-European defense and security systems. The establishment of a new position for the Commissioner for Defence and Space, the ReArm Europe Plan allocating an unprecedented €800 billion for defense spending, and other transformations in EU defense strategy signify a historic move, underscoring the increased urgency and need for actionable policy intelligence.
At this pivotal moment in EU policy, FiscalNote's expanded coverage gives customers immediate insight into funding shifts, procurement developments, and strategic policy direction across the EU, helping organizations make more informed decisions, reduce risk, and identify new opportunities in a fast-moving regulatory environment.

NOTE

FiscalNote Launches New Tool to Track EU Defense and Space Policy Amid Global Tensions

<ul>
<li>At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 (PCV20).</li>
<li>At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary&nbsp;Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses.</li>
<li>Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates.</li>
<li>Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formulation for Advancement to Potential Infant Phase 3 Program, Pending Topline VAX-31 Infant Phase 2 Study Readout.</li>
<li>Company Announces VAX-XL, Third-Generation PCV Candidate Designed to Further Expand Spectrum of Coverage</li>
</ul>

Biotech

Health Care

PCVX

Vaxcyte Announced Topline Results From Its Phase 2 Dose-finding Study Evaluating The Safety, Tolerability And Immunogenicity Of VAX-24 To Prevent Invasive Pneumococcal Disease, Compared To Prevnar 20 In Healthy Infants

<a href="https://www.globenewswire.com/Tracker?data=ma-kT6WnbgHL_DvvHe44TeFIMzVchRe8z-MUUNofR3A5fGKZDJAUgGao-vPcFfgu2r1di37Z8yjp0_G8mw_yA1hqRAVr1Y1QVeS_taW7JkGykuzwkDYnRJKLGFafdEhl_0YK3Bf4-YgwYI_7sOT8FX73azCvjc_zMihLonf0lr9aIYe5jXimLvp3tqxfQq8O-jin4ss-Xhl1jfc_f_cvDmml2R1ICcCx-Y8titSFMOZqtuT3UuLEOiRJIBKGpPCnOVEIEGnnoiQp79qGK4y4Es0FzRQWDVpFvED5f3Gjks0e99BpbOh3_JI3IpLnMHT8lCuoyPyRxHTISGfruO_bJCR7_w3vlzmRrA5nwaV3jl9dzWVt3Uj4YveqCNLtv0XyfSf7BT_TRGtMWofZShWeU9kcDmlKIeLsFNnVON_To_c=">TELA Bio, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and reconstructive surgery.
Designed for consistency in thickness, stretch, permeability, and handling while facilitating functional remodeling,1 the OviTex PRS portfolio now includes expanded size offerings, including a 25 x 30 cm oval and a 25 cm diameter circle. These larger configurations may reduce the need for multiple smaller pieces and have the potential to simplify more complex plastic and reconstructive procedures.

TELA

TELA Bio Launches Larger Surgical Mesh to Simplify Complex Reconstructive Procedures

ATCH

AtlasClear Holdings Shifts Transfer Agent To Dynamic Stock Transfer

Aclarion, Inc.,("Aclarion" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>, ACONW))),&nbsp;a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update on its strengthened positioning following the successful execution of strategic initiatives in Q1 2025.
"Aclarion significantly improved its financial and Nasdaq compliance positioning throughout Q1 such that we are now very well positioned to execute on our strategic plan of driving Nociscan to standard of care," said Jeff Thramann, MD, Executive Chairman of Aclarion. "The team is rapidly enrolling sites for the CLARITY trial, and we look forward to demonstrating that the use of Nociscan data improves surgical decision making and outcomes. We believe this will be a game changing catalyst for Aclarion and for how chronic low back pain is evaluated and treated."
Key Financial and Strategic Highlights:
<ul>
<li>Over $20 million raised in Q1 with nearly $15 million in cash on hand</li>
<li>Clean cap table, Zero debt,&nbsp;No preferred outstanding, No near-term warrant overhang.</li>
<li>Fully Nasdaq compliant, meeting both bid price and shareholder equity requirements</li>
<li>Clarity trial for Nociscan fully funded</li>
<li>Secured additional payer approvals in England</li>
<li>Expanded physician referral and commercial support for Nociscan in U.S.</li>
</ul>
"The Company is accelerating across all areas of execution," said Brent Ness, CEO of Aclarion. "In addition to strong momentum enrolling CLARITY sites, we've made meaningful commercial progress. We're also driving adoption in London, where we recently secured payer approvals and have built deep support among referring physicians and radiologists. Beyond London, we're actively pursuing new commercial agreements with imaging providers and MRI manufacturers to expand access to Nociscan. Clinical evidence generation remains a key pillar of our strategy, and 2025 will see several high-quality studies and publications reinforcing our leadership in the category. With our financing and compliance initiatives now behind us, the team is energized and focused on value creation."
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive discs are treated.

ACON

Aclarion Boosts Back Pain Diagnosis Tech After $20M Raise and Nasdaq Compliance Win

"This transaction is strategically and financially compelling for shareholders of both Mechanics Bank and HomeStreet," commented C.J. Johnson, CEO and President of Mechanics Bank. "We have completed a thorough due diligence process and look forward to welcoming HomeStreet's clients and employees to our company.

HMST

Mechanics Bank And HomeStreet Announce All-Stock Merger To Form $23B West Coast Banking Powerhouse

Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) reported quarterly losses of $(0.54) per share. This is a 135.76 percent decrease over earnings of $1.51 per share from the same period last year. The company reported $28.62 in sales this quarter. This is a 100.00 percent decrease over sales of $36.05 million the same period last year.

Earnings

NSYS

Nortech Systems Q4 EPS $(0.54) Down From $1.51 YoY, Sales $28.62 Down From $36.05M YoY

In a recent Twitch stream, Vivian Jenna Wilson, the estranged daughter of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk, has stirred controversy by labeling Tesla as a &#8216;Ponzi scheme&#8217;.
What Happened: Vivian Wilson made this statement during a live<a href="https://www.twitch.tv/videos/2417713896"> Twitch stream </a>with Hasan Piker, a prominent political commentator. Wilson criticized her father&#8217;s business model for Tesla, equating it to a Ponzi scheme due to its high P/E ratio as compared to other car companies. 
"Look up PE ratio and then look at Tesla stock compared to other car companies,&#8221; pointed out Wilson. &#8220;It&#8217;s not a car company, it&#8217;s a Ponzi scheme,&#8221; she stated.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="776" height="367" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31053258/Screenshot-2025-03-31-150112.png" alt="" class="wp-image-848863" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31053258/Screenshot-2025-03-31-150112.png 776w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31053258/Screenshot-2025-03-31-150112-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31053258/Screenshot-2025-03-31-150112-768x363.png 768w" sizes="(max-width: 776px) 100vw, 776px" /></figure>
Wilson&#8217;s comment that this term aptly describes Tesla&#8217;s business model has sparked widespread debate on X. Noted investor and media commentator Collin Rugg criticized Wilson and Piker, stating that the streamer &#8220;baited&#8221; Musk&#8217;s estranged daughter and agreed with her statements with &#8220;no evidence.&#8221;
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="591" height="381" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31053250/Screenshot-2025-03-31-150228.png" alt="" class="wp-image-848861" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31053250/Screenshot-2025-03-31-150228.png 591w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31053250/Screenshot-2025-03-31-150228-300x193.png 300w" sizes="(max-width: 591px) 100vw, 591px" /></figure>
Musk had earlier accused Piker of being a &#8220;fraud&#8221; for supporting Assassin&#8217;s Creed Shadows, a game he disapproved of. Wilson further talks about Musk overstating his gaming prowess during her conversation with Piker.
SEE ALSO:<a href="https://www.benzinga.com/25/03/44556536/irans-revolutionary-guard-officers-accused-of-stealing-21-million-in-crypto-during-investigation-in-a-corruption-case"> Iran&#8217;s Revolutionary Guard Officers Accused Of Stealing $21 Million In Crypto While Investigating A Corruption Case</a>
Why It Matters: This controversy comes at a time when Tesla&#8217;s stock has been under scrutiny. Despite a nearly 50% drop since mid-December, Tesla&#8217;s shares are still <a href="https://www.benzinga.com/25/03/44321998/why-ross-gerber-finds-tesla-stock-expensive-despite-its-50-plunge-fundamental-story-has-to-be-revalued">deemed too pricey</a> by seasoned investor Ross Gerber. Gerber, the president and CEO of Gerber Kawasaki Wealth &amp; Investment Management, expressed doubts about a rebound for Tesla&#8217;s stock this year.
Moreover, a&nbsp;<a href="https://www.benzinga.com/insights/news/25/03/44079504/comparing-tesla-with-industry-competitors-in-automobiles-industry">Benzinga </a>analysis from early March highlighted <a href="https://www.benzinga.com/insights/news/25/03/44079504/comparing-tesla-with-industry-competitors-in-automobiles-industry">Tesla&#8217;s position</a> in the competitive automobile industry. As per the analysis, Tesla&#8217;s Price to Earnings (P/E) ratio of&nbsp;143.62 on that date&nbsp;was 12.33x&nbsp;higher than the industry average, indicating the stock was priced at a premium level according to the market sentiment. 
Amid massive protests against Tesla across the U.S., Wedbush analyst Dan Ives stays hopeful of the EV maker&#8217;s recovery. Ives predicts weaker deliveries for Q1 but says, "This continues to be a moment of truth for Musk to navigate this brand tornado crisis moment and get onto the other side of this dark chapter for Tesla with much better days ahead we see for the story.&#8221;
The company, known for its electric vehicles and autonomous driving software, delivered nearly 1.8 million vehicles globally in 2024. However, the company&#8217;s high valuation, despite significant losses, continues to be a point of contention among investors.
Tesla stock lost 3.5% to close at $263.55 on Friday.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/tech/25/03/44552860/major-brands-resume-advertising-on-musks-x-amid-legal-pressure">Major Brands Resume Advertising On Musk&#8217;s X Amid Legal Pressure</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

TSLA

Elon Musk's Estranged Daughter Labels Tesla A 'Ponzi Scheme' Citing Stock's High P/E Ratio, Gets Called Out For 'No Evidence'

Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>), a clinical-stage biopharmaceutical company (the "Company'"), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial, titled, "Phase II study of Apalutamide with Carotuximab (ENV105) in Metastatic, Castration Resistant Prostate Cancer," began with the safety lead-in, which combined apalutamide, a standard of care for prostate cancer, with the Company's compound ENV105.
The second part of the study, which randomizes patients to receive either apalutamide alone or in combination with ENV105 is ongoing. The Company expects to announce the safety and efficacy data readout from the safety arm of the trial beginning in the first half of 2025.
"This is an important milestone in this trial as it helps to establish the safety and preliminary efficacy of the combination therapy with ENV105, which is essential in order to proceed with the randomized portion of the trial. We are very pleased with the rate of our progress thus far and are grateful to our participating centers for their continued dedication to the trial," said John Yu, M.D., Kairos CEO.
The Company is also validating biomarkers throughout the study to best identify those patients believed to have the most benefit for the combination therapy. In the meantime, the Company continues to enroll patients for the randomization arm of the study at key cancer centers in Los Angeles and Salt Lake City. The trial is supported by Kairos Pharma Ltd. and a grant from the National Cancer Institute (NCI).

KAPA

Kairos Advances Prostate Cancer Trial, Testing New Combo Treatment for Toughest Cases

Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) reported quarterly losses of $(4.25) per share which missed the analyst consensus estimate of $(3.56) by 19.38 percent. This is a 38.94 percent increase over losses of $(6.96) per share from the same period last year.

ELTX

Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into Q4 2025

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) with a Buy and maintains $30 price target.

Price Target

Reiteration

Analyst Ratings

TYRA

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

Gyre Therapeutics ("Gyre") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People's Republic of China ("PRC") has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary complications. The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP).
This regulatory milestone marks the expansion of pirfenidone beyond its established role in idiopathic pulmonary fibrosis (IPF) into the oncology supportive care space, offering a novel lung-protective strategy for cancer patients undergoing radiation therapy or immunotherapy.
In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's potential in this new indication.
Radiation-Induced Lung Injury (RILI): Radiation therapy is a cornerstone of lung cancer treatment. However, 5%–25% of patients experience lung damage due to radiation exposure, limiting the ability to escalate doses and thereby compromising treatment efficacy.
Checkpoint Inhibitor Pneumonitis (CIP): Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but 13%–19% of patients develop CIP. This condition accounts for approximately 35% of immune-related adverse event (irAE) deaths and often necessitates treatment discontinuation.
Currently, no targeted therapies exist for lung injuries caused by radiation or immunotherapy. Distinguishing between RILI and CIP is challenging, particularly when both occur concurrently. Corticosteroids remain the standard of care despite significant long-term side effects. By targeting and inhibiting fibrotic pathways, pirfenidone may address the root cause of lung injury progression, offering a new treatment option for patients receiving radiation or immunotherapy.

GYRE

Gyre Gets Green Light for Trial Aiming to Protect Cancer Patients' Lungs During Treatment

Shares of Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>), an energy infrastructure company that supports large-scale computing needs, including Bitcoin mining and high-performance computing, are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Monday.
The company has unveiled American Bitcoin Corp., a new subsidiary dedicated to large-scale Bitcoin mining and strategic reserve accumulation.
The development comes after Hut 8 contributed the majority of its ASIC miners in return for a dominant stake in a project supported by Eric Trump and Donald Trump Jr. The initiative was <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44556534/hut-8-and-eric-trump-launch-american-bitcoin-to-set-a-new-standard-in-bitcoin-mining" rel="noreferrer noopener">subsequently renamed American Bitcoin.</a>
The newly launched company aims to become the world&#8217;s most efficient dedicated Bitcoin miner. As part of this shift, all Bitcoin mining activities previously managed under Hut 8&#8217;s Compute segment will now operate under the American Bitcoin name.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44532830/rocket-lab-joins-us-space-forces-5-6-billion-launch-program-stock-soars" rel="noreferrer noopener">Rocket Lab Joins US Space Force&#8217;s $5.6 Billion Launch Program; Stock Soars</a>
Initially, American Bitcoin&#8217;s financial performance will be reflected within Hut 8&#8217;s consolidated reports.
Meanwhile, Hut 8 will continue as its sole infrastructure and operations partner, establishing long-term commercial agreements designed to ensure consistent revenue generation.
&#8220;From the start, we&#8217;ve backed our conviction in Bitcoin—personally and through our businesses,&#8221; said Donald Trump Jr.
&#8220;But simply buying Bitcoin is only half the story. Mining it on favorable economics opens an even bigger opportunity. We&#8217;re excited to bring investors into that equation through a platform engineered to execute on this thesis and deliver real, tangible participation in Bitcoin&#8217;s growth.&#8221;
American Bitcoin aims to achieve a computing capacity exceeding 50 exahashes per second (EH/s) while keeping its fleet efficiency under 15 joules per terahash (J/TH), with a goal of becoming a publicly listed company.
The company&#8217;s leadership team will include Mike Ho as Executive Chairman, Matt Prusak as CEO, and Eric Trump as Chief Strategy Officer. The Board of Directors will feature Ho, Asher Genoot, Justin Mateen, and Michael Broukhim.
Under long-term agreements, Hut 8 will provide colocation services, operational management, and other support functions for American Bitcoin. The parent company will oversee daily operations through a shared services contract.
Price Action: HUT shares traded higher by 7.08% at $12.55 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44533913/lockheed-martin-and-google-partner-to-advance-ai-in-defense" target="_blank" rel="noreferrer noopener">Lockheed Martin And Google Partner To Advance AI In Defense</a></li>
</ul>
Image via Shutterstock.

President Trump's Sons Partner With Hut 8 To Unveil American Bitcoin For Large-Scale Bitcoin Mining

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Niagen Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>) with a Buy and maintains $11 price target.

NAGE

HC Wainwright & Co. Reiterates Buy on Niagen Bioscience, Maintains $11 Price Target

USAR

USA Rare Earth Deploys Advanced Innovations Lab At Oklahoma Manufacturing Facility

Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 41.3 percent decrease over losses of $(0.46) per share from the same period last year.

CABA

Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) with a Buy and maintains $20 price target.

TRDA

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) with a Buy and maintains $20 price target.

Comments

Kaixin Hldgs

Noticias

Últimas noticias sobre Kaixin Hldgs (NASDAQ:KXIN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL